BACKGROUND: Comparative studies suggest that DHA may have stronger serum triglyceride-lowering effects than EPA; however, the molecular basis for this differential effect remains unexplored in humans. Differential regulation of lipogenesis and triglyceride clearance are 2 possible mechanisms of action. OBJECTIVES: We compared the effects of EPA and DHA supplementation on serum triglycerides, markers of lipogenesis, and lipoprotein lipase (LPL) activity in adults participating in a double-blind, multiarm, placebo-controlled parallel-group randomized trial. Lipogenesis was assessed with the lipogenic index and compound specific isotope analysis (CSIA). METHODS:Young, healthy normolipidemic men and women (n = 89; 21.6 ± 0.23 y; mean ± SEM) were randomly allocated into 1 of 3 supplement groups for 12 wk: 1) olive oil, 2) ∼3 g EPA/d, and 3) ∼3 g DHA/d. Omega-3 supplements were provided in triglyceride form. Blood was collected before and after supplementation for the analysis of fatty acids and preheparin LPL activity. Variations in the 13C:12C ratio (δ13C) of palmitate (16:0) and linoleate (18:2n-6) were measured by CSIA. RESULTS:DHA supplementation reduced blood triglycerides (0.85 ± 0.04 mmol/L to 0.65 ± 0.03 mmol/L; P < 0.01), with no change seen with EPA supplementation. DHA supplementation did not change the lipogenic index or δ13C-16:0, whereas EPA supplementation increased the lipogenic index by 11% (P < 0.01) and δ13C-16:0 (P = 0.03) from -23.2 ± 0.2 to -22.8 ± 0.2 milliUrey ± SEM. CONCLUSIONS: Reduced triglyceride concentrations after DHA supplementation are associated with increased LPL activity, whereas the null effect of EPA supplementation on blood triglycerides may stem from the concomitant increases in lipogenesis and LPL activity. Further investigation of the differential triglyceride-lowering effects of EPA and DHA is warranted in both normolipidemic and hyperlipidemic individuals. This trial was registered at clinicaltrials.gov as NCT03378232.
RCT Entities:
BACKGROUND: Comparative studies suggest that DHA may have stronger serum triglyceride-lowering effects than EPA; however, the molecular basis for this differential effect remains unexplored in humans. Differential regulation of lipogenesis and triglyceride clearance are 2 possible mechanisms of action. OBJECTIVES: We compared the effects of EPA and DHA supplementation on serum triglycerides, markers of lipogenesis, and lipoprotein lipase (LPL) activity in adults participating in a double-blind, multiarm, placebo-controlled parallel-group randomized trial. Lipogenesis was assessed with the lipogenic index and compound specific isotope analysis (CSIA). METHODS: Young, healthy normolipidemic men and women (n = 89; 21.6 ± 0.23 y; mean ± SEM) were randomly allocated into 1 of 3 supplement groups for 12 wk: 1) olive oil, 2) ∼3 g EPA/d, and 3) ∼3 g DHA/d. Omega-3 supplements were provided in triglyceride form. Blood was collected before and after supplementation for the analysis of fatty acids and preheparin LPL activity. Variations in the 13C:12C ratio (δ13C) of palmitate (16:0) and linoleate (18:2n-6) were measured by CSIA. RESULTS:DHA supplementation reduced blood triglycerides (0.85 ± 0.04 mmol/L to 0.65 ± 0.03 mmol/L; P < 0.01), with no change seen with EPA supplementation. DHA supplementation did not change the lipogenic index or δ13C-16:0, whereas EPA supplementation increased the lipogenic index by 11% (P < 0.01) and δ13C-16:0 (P = 0.03) from -23.2 ± 0.2 to -22.8 ± 0.2 milliUrey ± SEM. CONCLUSIONS: Reduced triglyceride concentrations after DHA supplementation are associated with increased LPL activity, whereas the null effect of EPA supplementation on blood triglycerides may stem from the concomitant increases in lipogenesis and LPL activity. Further investigation of the differential triglyceride-lowering effects of EPA and DHA is warranted in both normolipidemic and hyperlipidemic individuals. This trial was registered at clinicaltrials.gov as NCT03378232.
Authors: Giulia Cisbani; Alex Koppel; Adam H Metherel; Mackenzie E Smith; Kankana N Aji; Ana C Andreazza; Romina Mizrahi; Richard P Bazinet Journal: Lipids Date: 2022-01-24 Impact factor: 1.880
Authors: Anandita Pal; Abrar E Al-Shaer; William Guesdon; Maria J Torres; Michael Armstrong; Kevin Quinn; Traci Davis; Nichole Reisdorph; P Darrell Neufer; Espen E Spangenburg; Ian Carroll; Richard P Bazinet; Ganesh V Halade; Joan Clària; Saame Raza Shaikh Journal: FASEB J Date: 2020-06-24 Impact factor: 5.191
Authors: Dominique Turck; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; John Kearney; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Pelaez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; Thomas Frenzel; Marina Heinonen; Rosangela Marchelli; Monika Neuhäuser-Berthold; Morten Poulsen; Miguel Prieto Maradona; Josef Rudolf Schlatter; Henk van Loveren; Emanuela Turla; Helle Katrine Knutsen Journal: EFSA J Date: 2021-01-19
Authors: Anandita Pal; Adam H Metherel; Lauren Fiabane; Nicole Buddenbaum; Richard P Bazinet; Saame Raza Shaikh Journal: Nutrients Date: 2020-12-02 Impact factor: 5.717
Authors: Safi U Khan; Ahmad N Lone; Muhammad Shahzeb Khan; Salim S Virani; Roger S Blumenthal; Khurram Nasir; Michael Miller; Erin D Michos; Christie M Ballantyne; William E Boden; Deepak L Bhatt Journal: EClinicalMedicine Date: 2021-07-08
Authors: Maria Jose de la Torre-Aguilar; Antonio Gomez-Fernandez; Katherine Flores-Rojas; Pilar Martin-Borreguero; María Dolores Mesa; Juan Luis Perez-Navero; Mónica Olivares; Angel Gil; Mercedes Gil-Campos Journal: Front Nutr Date: 2022-03-29